- Home
- GORV vs NRXP Comparison
GORV vs NRXP Comparison
Compare GORV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- NRXP
- Stock Information
- Founded
- GORV 1976
- NRXP 2015
- Country
- GORV United States
- NRXP United States
- Employees
- GORV N/A
- NRXP N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- NRXP Health Care
- Exchange
- GORV Nasdaq
- NRXP Nasdaq
- Market Cap
- GORV 25.3M
- NRXP 32.6M
- IPO Year
- GORV 2015
- NRXP N/A
- Fundamental
- Price
- GORV $0.24
- NRXP $3.27
- Analyst Decision
- GORV Hold
- NRXP Strong Buy
- Analyst Count
- GORV 2
- NRXP 4
- Target Price
- GORV $2.00
- NRXP $28.50
- AVG Volume (30 Days)
- GORV 2.3M
- NRXP 215.7K
- Earning Date
- GORV 08-15-2025
- NRXP 08-13-2025
- Dividend Yield
- GORV N/A
- NRXP N/A
- EPS Growth
- GORV N/A
- NRXP N/A
- EPS
- GORV N/A
- NRXP N/A
- Revenue
- GORV $767,257,000.00
- NRXP N/A
- Revenue This Year
- GORV $15.65
- NRXP N/A
- Revenue Next Year
- GORV $20.54
- NRXP N/A
- P/E Ratio
- GORV N/A
- NRXP N/A
- Revenue Growth
- GORV N/A
- NRXP N/A
- 52 Week Low
- GORV $0.13
- NRXP $1.10
- 52 Week High
- GORV $3.56
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- GORV 48.60
- NRXP 53.62
- Support Level
- GORV $0.22
- NRXP $2.90
- Resistance Level
- GORV $0.26
- NRXP $3.53
- Average True Range (ATR)
- GORV 0.02
- NRXP 0.20
- MACD
- GORV 0.00
- NRXP -0.04
- Stochastic Oscillator
- GORV 51.29
- NRXP 58.73
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.